Trajan Scientific and Medical (Trajan) was pleased to support its distribution partners Kinesis Ltd and Gulf Analytical Supplies FZE at ArabLab 2016 held at the Dubai International Convention and Exhibition Centre from 20 - 23 March 2016.
With over 10,000 visitors from 101 countries visiting 1,000 exhibiting companies, it was a fantastic opportunity to for Trajan to join Kinesis Ltd and Gulf Analytical Supplies through both seminar presentation and booth presence.
Mr Andy Hall, Trajan’s Distribution and Operations Manager, Europe, Middle East, Africa, said end-users, manufacturers and distributors had traveled from all over the region and beyond to attend the event, and the quality of discussions about future opportunities to work with Trajan products was very positive.
Together with Mr Akram Hussain from Kinesis Ltd, Mr Hall presented Trajan’s SGE eVol, world’s first digital analytical syringe in a delegate seminar, explaining the features and benefits of using eVol compared to traditional laboratory workflows. Further details about this innovative device can be found in the seminar presentation notes below.
“At Arablab 2016 Trajan’s distributors in the region came away with strong new leads and contacts, and I am confident these engagements will to a sustained growth for their sales of Trajan’s SGE brand chromatography products,” said Mr Hall.
Photo: Mr Andy Hall, Trajan's Distribution and Operations Manager, Europe, Middle East, Africa, presenting eVol with Kinesis at ArabLab 2016
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.